New drug aims to ease heart blockage in rare HCM form
NCT ID NCT07103655
First seen Jan 27, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tests a drug called mavacamten in 132 people with hypertrophic cardiomyopathy (HCM) that blocks the lower part of the heart. The goal is to see if the drug reduces pressure inside the heart during a breathing maneuver over 36 weeks. Participants must have a thickened heart wall and meet specific criteria. The drug is already used for other HCM types, but this study focuses on a less common blockage location.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.